Retatrutide is an investigational drug studied for weight loss, diabetes, and fatty liver. Learn what is retatrutide used for, its mechanism, and safety.
Retatrutide is an investigational drug being studied for weight loss, type 2 diabetes, and fatty liver disease. It is not approved by the U.S. Food and Drug Administration (FDA) for any human use as of 2025. Early clinical trials show it can produce substantial weight loss by targeting three hormone receptors at once.
If you are asking what is retatrutide used for, the short answer is: it is a research treatment for obesity and metabolic conditions, not a marketed medication.
What Does Retatrutide Do?
Retatrutide is a triple agonist. It activates three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. This retatrutide mechanism of action is different from semaglutide, which only hits GLP-1, and tirzepatide, which hits GIP and GLP-1.
By activating the glucagon receptor, retatrutide may increase energy expenditure and fat burning. It also slows stomach emptying and reduces appetite, similar to other GLP-1 drugs. The combination could explain why it has produced larger weight loss than older medications in trials.
Retatrutide for Weight Loss: What the Trials Show
In a phase 2 trial published in 2023, adults with obesity who took retatrutide lost an average of 24% of their body weight over 48 weeks at the highest dose. That is among the largest weight loss effects ever seen with a medication.
Researchers are also studying retatrutide for women and men. So far, trial results have not shown major differences between sexes, but more data is needed. The drug is not yet available by prescription.
If you are looking for a new weight loss drug retatrutide, know that it remains experimental. You cannot buy it legally from a U.S. pharmacy today.
Retatrutide for Diabetes and Fatty Liver
Retatrutide for diabetes is being tested in people with type 2 diabetes. In early trials, it lowered blood sugar and HbA1c while also causing weight loss. That dual effect is promising for people who need both glucose control and weight management.
Retatrutide fatty liver research is also underway. Some studies show reductions in liver fat and improvements in markers of MASH (metabolic dysfunction-associated steatohepatitis). However, these results are preliminary and not yet confirmed in large phase 3 trials.
How Retatrutide Compares to Other Weight Loss Drugs
| Drug | Receptors targeted | FDA status | Average weight loss in trials |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | Approved | ~15% |
| Tirzepatide (Zepbound) | GIP + GLP-1 | Approved | ~21% |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational | ~24% |
| Liraglutide (Saxenda) | GLP-1 | Approved | ~8% |
These numbers come from different trials with different designs, so they are not direct comparisons. Still, retatrutide appears to be in a higher weight-loss tier than currently approved options.
What Is in Retatrutide and How It Is Taken
Retatrutide is a synthetic peptide, not a pill. It is given as a once-weekly subcutaneous injection in clinical trials. Doses start low and increase slowly to reduce side effects.
Common side effects include nausea, vomiting, diarrhea, and constipation. These are typical of GLP-1 drugs. Some people also report injection site reactions.
Researchers sometimes ask what is bacteriostatic water for injection used for when preparing peptide solutions, but retatrutide is supplied as a finished injectable pen in trials. It is not a do-it-yourself peptide.
Safety, Side Effects, and Related Research
Retatrutide is not FDA-approved, so it has no established safety profile for general use. Clinical trials monitor participants closely for pancreatitis, gallbladder issues, and hypoglycemia.
People with a history of thyroid cancer or pancreatitis should be cautious. Always consult a healthcare professional before considering any weight loss drug, especially an investigational one.
Some online sellers claim to offer retatrutide for sale, but these products are unregulated and may be unsafe. Avoid buying peptides from unknown sources.
Retatrutide is not the only peptide people ask about. Many researchers also search for what is igf-1 lr3 used for, but that compound works on IGF-1 receptors and has no approved human use.
Others ask what is aod 9604 used for, a fragment of growth hormone studied for fat loss. It is not the same as retatrutide.
You may also see what is cjc 1295 ipamorelin used for, which is a growth hormone secretagogue combination. These are all experimental and not FDA-approved for weight loss.
For handling any peptide in a lab, people ask what is bac water used for, but that is a solvent, not a drug.
Frequently Asked Questions
Is retatrutide approved by the FDA?
No. Retatrutide is not approved by the FDA for any use as of 2025. It is still being studied in clinical trials for weight loss, diabetes, and fatty liver disease. You cannot get a prescription for it in the United States.
How does retatrutide work for weight loss?
Retatrutide activates three hormone receptors: GIP, GLP-1, and glucagon. This triple action reduces appetite, slows stomach emptying, and may increase calorie burning. In trials, it produced up to 24% average weight loss over 48 weeks.
What are the side effects of retatrutide?
Common side effects include nausea, vomiting, diarrhea, and constipation. More serious risks may include pancreatitis and gallbladder problems. Because it is investigational, long-term safety is not yet known. Consult a healthcare professional for personalized advice.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.